IJNRD.ORG ISSN : 2456-4184
INTERNATIONAL JOURNAL OF NOVEL RESEARCH AND DEVELOPMENT (IJNRD) | IJNRD.ORG
An International Open Access, Peer-reviewed, Refereed Journal

Cardiac Embolic Stroke Etiology Risk Factors and Management

ABDULLAHI IBRAHIM UMAR, Dr. Sandip Prasad Tiwari, Dr .Rupali Bharti Soa, Mrs. Rajni Yadav
B.pharmacy, Pharmacy Phd, Pharm D, Pharmacy M .Pharmacy
kalinga university naya raipur indian

Abstract
A cardiac embolism stroke results to the migration of blood clot originating from the heart to the brain, causing vascular obstruction and subsequent neurological damage. This review delves into the etiology, risk factors, and management strategies associated with cardiac embolism strokes.
Etiology:
The primary contributors to cardiac embolism strokes include atrial fibrillation (AF), valvular heart disease, cardiomyopathy, endocarditis, and the formation of left ventricular thrombi. Understanding these underlying cardiac conditions is crucial for targeted prevention and intervention.
Risk Factors:
Key risk factors encompass age, with an increased susceptibility in the elderly population. Atrial fibrillation emerges as a prominent risk factor, alongside hypertension, diabetes, smoking, and history of prior strokes and transient ischemic attacks. Management strategies must be approach these risk factors comprehensively.
Management:
Effective management involves a multi-faceted approach. Anticoagulant medications, such as warfarin or direct oral anticoagulants, play a pivotal role in preventing clot formation. Antiplatelet medications, particularly aspirin, may be prescribed. Control and treatment of underlying conditions, including hypertension and diabetes, are paramount. Cardioversion and surgical interventions, such as valve replacement or repair, are considered in specific cases. Life style Modifications, Including regular exercise and a healthy diet, contribute Significantly to reducing stroke risk. Close monitoring, frequent medical follow-ups, and patient education Proper are essential components of the holistic management strategies.
In conclusion, the etiology, risk factors, and management of cardiac embolism strokes require a comprehensive and individualized approach. Collaboration between healthcare professionals and patients is fundamental to mitigating risk factors, implementing effective treatments, and enhancing overall outcomes in individuals at risk of or affected by cardiac embolism strokes.

Keyword
Cardiac embolism stroke and management

CHPTER 1
Introduction
A stroke, also known as a cerebrovascular accident (CVA), occurs when there is disruption of the blood supply from the brain, leading to damage or death of brain cells. Strokes Is a classified in to different types based on their causes and characteristics. The main two types of strokes are ischemic strokes and hemorrhagic strokes.
Ischemic Stroke:

Thrombotic Stroke: occurs when a blood clot (thrombus) forms from part of the arteries supplying blood from the brain. The clot usually forms a narrowed or damaged blood vessel.
Embolic Stroke: This happened when a blood clot or other debris forms another some part of the body (often from heart) and travels through the bloodstream to brain, blocking a blood vessel.
Hemorrhagic Stroke
Intracerebral Hemorrhage: This occurs when there is bleeding within the brain tissue do to the rupture of the blood vessel. High blood pressure is the usually cause of this type of stroke.
Subarachnoid Hemorrhage: is type of stroke involves bleeding from the space between the brain and the thin tissues that cover it. It is often caused by the rupture of an aneurysm (a weakened area in a blood vessel).
Transient Ischemic Attack (TIA):
referred to as a "mini-stroke," a TIA is a temporary disruption of blood flow from the brain. Symptoms are like those of the stroke but resolve within a short period (usually within a few minutes to 24 hours).
Stroke symptoms can include sudden numbness or weakness the face, arm, and leg; confusion; trouble speaking or understanding speech; difficulty seeing in one or both eyes; and severe headache.
It's crucial to seek immediate medical attention if you are suspect someone having a stroke, as prompt treatment can maintain damage and improve outcomes. The classification of strokes helps guide treatment decisions, as the management of ischemic and hemorrhagic strokes may differ. Additionally, identifying the underlying cause of the stroke is essential of preventing future that occurrences and managing risk factors.
An embolism refers to the sudden blockage of a blood vessel by an embolus, which is a mass of foreign material, such as blood clot, air bubble, and fat globule, or other debris that travels through the bloodstream and lodges in a blood vessel. The blockage disrupts blood flow to the affected area, leading to tissue damage or death if not promptly addressed.
There are Some types of embolisms, including:
a) Cerebral Embolism
b) Systemic Embolism
c) Pulmonary Embolism
d) Air Embolism
e) Arterial Embolism
Cerebral Embolism: This type of embolism occurs when an embolus travels to the brain and blocks a blood vessel, leading to a stroke. The embolus can be blood clot, fat, air, and other material.
Systemic Embolism: This refers to the embolization of a clot and other material to some parts of the body, causing blockages in various organs or tissues.
Pulmonary Embolism (PE): This occurs when an embolus, usually blood clot that forms in the legs (deep vein thrombosis), breaks loose and travels to the lungs, causing a blockage in the pulmonary arteries.
Air Embolism: An air embolism is a medical disorder that occurs when air bubbles enter the bloodstream and travel to vital organs, causing blockages and potentially serious consequences. Normally, the bloodstream is a closed system, and the presence of air in the circulatory system can disrupt normal blood flow.
Arterial Embolism: is a medical disorder that occurs when an embolus, which is a detached blood clot, fat globule, air bubble, or other foreign material, travels through the bloodstream and becomes lodged in an artery, blocking blood flow of The arteries is the vessels that can be carry oxygenated blood away from the heart to the some various parts of the body.
embolus can categories from different sources, including:
i. Blood Clot
ii. Air
iii. Foreign Material
iv. Fat
v. Cholesterol
Blood Clots: Often originating from the heart (sucssh as in cases of atrial fibrillation or after a heart attack), or some parts of the circulatory system.
Air: Air embolisms can be occur during access medical procedures, such as surgery or certain diagnostic tests, where air enters the bloodstream.
Foreign Material: Other particles or substances can also travel
Fat: Long Bone Fractures: Fat embolism can be occur when bone marrow or fat globules enter the bloodstream after a fracture, often long bones like the femur.

Cholesterol : Atheroembolism: Plaque or debris from atherosclerotic plaques in larger arteries can crack loose and travel to smaller vessels.

CHAPTER2

Cardiac Embolism

source of embolism in the heart is the left atrial appendage , is a small pouch from the left atrium. The embolus can travel through the arteries until it becomes lodged in a smaller blood vessel, causing an obstruction.

This type of embolism can have being serious consequences, particularly when the embolus reaches vital organs such as brain, lungs, or other organs. When a cardiac embolism will affects blood flow to the brain, it can result in a stroke. If it affects the blood vessels from the lungs, it may cause a pulmonary embolism. The severity of the consequences depends on the embolus and the specific blood vessel it blocks.

Cardiac embolism is associated with certain medical disorder that is increase the risk of blood clot formation, such as atrial fibrillation (a heart rhythm disorder), heart valve disorders, and certain types of cardiomyopathy (heart muscle diseases). Individuals people with these conditions may be will prescribed anticoagulant medications to decrease the high risk of blood clot formation and embolism. symptoms and consequences of cardiac embolism can vary widely depending on a location and size of an embolus. Common symptoms are include sudden onset of neurological deficits (such as weakness and paralysis on one side of the body), difficulty breathing, chest pain, and other signs of organ dysfunction.



Fig1Cardiac blocked

Cardiac embolism refers to the formation and migration of the blood clot (embolus) originating from heart and other circulatory system. The common source of cardiac Embolic is the left atrium, particularly in individuals with certain heart conditions. some different types of cardiac embolism based on specific cardiac conditions that predispose individuals to the formation of Embolic. Some of the notable types include:

1. Atrial Fibrillation
2. Mitral Stenosis
3. Left ventricular Aneurysm
4. Cardiomyopathy
5. Prosthetic Heart Valves
6. Infective Endocarditis
7. Left Atrial Thrombus

Atrial Fibrillation (AF): Atrial fibrillation is a common heart rhythm disorder characterized by irregular and rapid atrial contractions. Blood may pool in the atria during AF, leading to the formation of blood clots. If a clot dislodges, it can travel by the brain also causing a stroke.

Mitral Stenosis: this condition where the mitral valve, located between the left atrium and left ventricle, narrows and restricts blood flow. Blood stasis in the left atrium can result in clot formation, leading to embolism.

Left Ventricular Aneurysm: Aneurysms are abnormal bulges in the space of the heart chambers. In case of left ventricular aneurysm, blood stasis can occur, promoting clot formation and subsequent embolism.

Cardiomyopathy: Conditions that cause of the heart muscle to become enlarged, thickened, or weakened can induce the risk of clot formation. These clots may then embolism to some parts of the body.

Prosthetic Heart Valves: Individuals with have artificial heart valves are at an increased risk of forming blood clots on the valve surface. These clots can crack loose and travel to other organs, causing embolism.

Infective Endocarditis: This is an germs of the inner lining from the heart chambers and heart valves. Clots can form on infected heart valves and embolism other organs.

Left Atrial Thrombus: A thrombus (blood clot) in the left atrium may develop in individuals with certain heart conditions, and if it dislodges, it can be cause embolism.

Note: It's important to note the consequences of cardiac embolism can be severe, particularly when the embolus reaches critical organs such as the brain, leading to strokes or other organ damage. Treatment and prevention strategies often involve anticoagulant medications is reduce the risk of clot formation and embolism. Individuals with known cardiac conditions that enhance the risk of embolism may receive prophylactic Anticoagulation therapy under the guidance of healthcare professionals.

Etiology

Cardiac embolism refers to the formation and subsequent dislodgment of the blood clot (embolus) originating from the heart. The etiology, or the cause, of cardiac embolism, is often associated with specific conditions or risk factors that also can be predispose individuals to development of blood clots within to heart chambers. The top common condition linked to cardiac embolism is atrial fibrillation (AF), a type of irregular heart rhythm.

1. Atrial Fibrillation(AF)
2. Atrial Flutter
3. Valvular Heart Diseases
4. Cardiomyopathy
5. Endocarditis
6. Myocardial Infarction
7. Left Arterial Appendage Thrombus
8. Hypercoagulable state

Atrial Fibrillation (AF): AF is an common heart rhythm characterized by rapid and irregular contractions of the atria (upper chambers of the heart). In AF, blood may pool in the atria, leading to the formation of blood clots. If a clot dislodges, it can travel through bloodstream, caused a blockage in smaller blood vessels, particularly in the brain, leading to a stroke.

Atrial Flutter: Atrial flutter is another arrhythmia that can contribute the formation of blood clots in the atria, potentially leading to embolism.

Valvular Heart Disease: Conditions affecting the heart valves, such as mitral stenosis or artificial heart valves, can be disrupt normal blood flow and create a favorable environment for clot formation.

Cardiomyopathy: Conditions that affect the heart muscle, such as dilated or hypertrophic cardiomyopathy, can be enhance the risk of the clot formation.

Endocarditis: Infective endocarditis, an infection occur from the heart valves or inner lining of the heart, can be lead to the formation of clots.

Myocardial Infarction (Heart Attack): A heart attack that can damage the heart muscle also create conditions that favor clot formation.

Left Atrial Appendage Thrombus: The left atrial appendage is a little pouch in the left atrium where blood stasis can occur, increasing the risk of clot formation, particularly in individuals with AF.

Hypercoagulable States: Some individuals may have a higher tendency to form blood clots due to inherited or acquired conditions that make their blood more prone to clotting.

CHAPTER 3

Pathophysiology

Cardiac embolism refers to the formation and subsequent release of the blood clot (embolus) within to the heart, which then travels through the bloodstream and lodges in a blood vessel, causing obstruction. The Pathophysiology of cardiac embolism involves several key steps:

a. Formation of Thrombus
b. Embolization
c. Travel Through Blood Vessel
d. Lodging Atries
e. Ischemia and Tissue Damage

Formation of Thrombus: Thrombi can form within the heart chambers, particularly in the atria, where blood flow may be sluggish or turbulent. Conditions that predispose individuals to thrombus formation include atrial fibrillation (a common arrhythmia), myocardial infarction (heart attack), dilated cardiomyopathy, and endocarditis.

Embolization: Once a thrombus forms, it can crack free from its site of origin and become an embolus. The embolus is then carried by the bloodstream to some parts of the body.

Travel through Blood Vessels: The embolus travels through the bloodstream, following the path of blood flow. If the embolus is small enough, it may travel through the smaller arteries without causing significant blockages. However, if the embolus is larger, it can get lodged in narrower blood vessels.

Lodging in Arteries: The embolus eventually lodges in a blood vessel, causing an obstruction. The lodging site depends on the range of the embolus and the anatomy of the bloodvessels. Common sites for embolism include arteries in the brain, lungs, or extremities.

Ischemia and Tissue Damage: Once the embolus obstructs blood flow in the target artery, it leads to ischemia (lack of blood supply) in the downstream tissue. This ischemia can cause tissue damage, and severity of the damage depends on factors such as size of the embolus and the duration of blood



Fig2 Pathophysiology of Cardiac Embolism

Risk Factors Of Cardiac Embolism

Cardiac embolism refers to the blockage of blood vessels by an embolus (a clot or other material) that originates from the heart. The risk factors of cardiac embolism are depended associated with disorder that enhance the likelihood of a blood clot formation in heart. Some others key risk factors include:

i. Atrial Fibrillation(AF)
ii. Recent Myocardial Infarction
iii. Heart Failure
iv. Cardiomyopathy
v. Endocarditis
vi. Age
vii. Hypercoagulable
viii. Diabetes
ix. Hypertension
x. Smoking
xi. Obesity
xii. Sedentary Lifestyle

Atrial Fibrillation (AF): AF is a common heart rhythm disorder characterized by irregular and rapid heartbeats. It can be lead to the formation of blood clots in the atria, which may then dislodge and travel to some other parts of the body.

Valvular Heart Disease: Certain heart valve conditions, such as mitral stenosis or mechanical heart valves, can create turbulent blood flow and enhance the risk of blood clot formation.

Recent Myocardial Infarction (Heart Attack): A recent heart attack can lead to the formation of blood clots within the damaged areas of the heart.

Heart Failure: In cases of heart failure, the heart may not pumping blood efficiently, leading to blood stasis and an increased risk of clot formation.

Cardiomyopathy: Conditions affecting the heart muscle, such as dilated or hypertrophic cardiomyopathy, can disrupt a normal blood flow and contribute to clot formation.

Endocarditis: This is an infection of the heart valves and lining of the heart, which can result the formation of clots.

Age: risk of cardiac embolism generally increases with age, particularly in individuals over 75 years old. can elevate risk of cardiac embolism.

Diabetes: Individuals with diabetes have an enhance risk of cardiovascular diseases, including conditions that may lead to cardiac embolism.

Hypertension (High Blood Pressure): Critical High Blood Pressure can also damage blood vessels and Involve to the formation of clots.

Smoking: Smoking is an main risk factor for enhance cardiovascular disorder, Including they may lead to embolism.

Obesity: Excess body weight can also contribute to various cardiovascular risk factors, Including hypertension and diabetes.

Sedentary Lifestyle: Lack of physical activity is an associated with increased risk of cardiovascular diseases and may contribute to development of clots.

Note: It's important to note that more of these risk factors are Influence, and addressing them through lifestyle modifications and medical management can help decrease some risk of cardiac embolism. Difference people have multiple risk factors or specific heart
conditions may require closer monitoring and medical intervention to manage their risk effectively



Fig3 Risk Factors Cardiac Embolic Stroke

Epidemiology

the American Heart Association's efforts in monitoring and evaluating data on heart disease and stroke at United States, particularly in context of the 2023 Statistical Update. The update reflects a year-long collaborative effort involving volunteer clinicians, scientists, government professionals, and American Heart Association staff members. The focus extends beyond cardiovascular health to address the impact of

structural racism on public health, acknowledging its role in perpetuating disparities in an various aspects of life.

The 2023 edition also incorporates additional information on COVID-19, considering its implications on heart health. Moreover, there's an emphasis on promoting health equity across different domains, recognizing the importance of addressing disparities in access to healthcare, education, income, housing, and other factors crucial for overall well-being.

CHAPTER 4
Management

Diagnosis:

The diagnosis of a stroke caused by a cardiac embolism involves a combination of medical history , physical examination of the patient, and various diagnostic tests. Cardiac embolism refers to the formation of blood clot from to the heart that travels through a blood stream and lodges in blood vessel from the brain, lead to form stroke. Here's an overview of the diagnosis process:

a) Medical History
b) Physical Examination
c) Diagnostic Imaging
d) Electrocardiogram(ECG or KCG)
e) Echo cardiogram
f) Blood Test
g) Carotid Ultrasound
h) Holter Monitor or Event Recorder
i) Risk Factors Assessment

Medical History: The healthcare provider will take a detailed of medical history from patient, including information about the patient's risk factors from stroke. The may include abnormal body function such as atrial fibrillation (a heart rhythm disorder that enhance the risk of blood clots) and history of previous strokes and transient ischemic attacks (TIAs).

Physical Examination:A thorough physical examination will be conducted to assess neurological function and identify any signs of stroke. This may include evaluating strength, coordination, speech, and vision.

Diagnostic Imaging:CT Scan or MRI: These imaging tests also help to determine the main type of stroke (ischemic or hemorrhagic) and locate the affected area of the brain.

CT Angiography (CTA) or Magnetic Resonance Angiography (MRA): These tests provide detailed images of an blood vessels in the brain, helping to identify any blockages or abnormalities.

Electrocardiogram (ECG or EKG):

An ECG also measures the electrical activity of the heart. It can help identify irregular heart rhythms, such as atrial fibrillation, which may Involve to the formation of blood clots.



Fig4 ECG Diagnosis Cardiac Embolic Stroke

Echo cardiogram: This ultrasound by heart to provides detailed images from the heart's structure and function. A transesophageal echo cardiogram (TEE) may be performed in other cases for a more detailed view of an heart, especially the atria where blood clots may form.

Fig5 Echo cardiogram Cardiac Embolic Stroke

Blood Tests:

Blood tests may be conducted to assess various factors, including clotting factors and cholesterol levels.

Carotid Ultrasound: This test uses sound waves to create images of carotid arteries in the neck, that may supply blood to the brain. It helps identify any narrowing or blockages in these arteries.

Holter Monitor or Event Recorder: These devices can be used to monitor the heart's electrical activity over an extended period, helping to detect intermittent irregularities.

Risk Factor Assessment: Assessment of additional risk factors, such as Smoke, and High blood pressure, Diabetes, and lifestyle factors, may be considered to guide treatment and prevention strategies.

Note: The combination of these diagnostic tools helps healthcare professionals determine the cause of the stroke, including whether it resulted from a cardiac embolism.

Treatment strategies will then be tailored based on the underlying cause to prevent future strokes and manage the patient's overall health

Treatment

Pharmacotherapy:

The treatment of a cardiac embolism stroke involves addressing the underlying cause, which is typically a blood clot that originates in the heart and travels to the brain. Here are some general approaches to the treatment of cardiac embolism stroke:

a. Anticoagulant Medications (Blood Thinners)
b. Antiplatelet Medication
c. Thrombolytic Therapy(Clot -boating Medication)
d. Surgery or Intervention Procedures
e. Management of Underlying Heart Conditions
f. Rehabilitation and Supportive Care

Anticoagulants, such as heparin or warfarin, are prescribed to prevent further blood clot formation and decrease the risk of recurrent strokes. These Substance work by inhibiting the formation of blood clots.

Pharmacokienetic Anticoagulant:

The Pharmacokienetic of anticoagulant drugs refers to how these medications are absorbed, distributed, metabolized, and eliminated by the body. Anticoagulants is a Medication that prevent blood clot formation, and they are commonly used to treat or prevent conditions such as deep vein thrombosis (DVT), pulmonary embolism, and atrial fibrillation. Examples of anticoagulant drugs include warfarin, heparin, and direct oral anticoagulants (DOACs) such as rivaroxaban and apixaban.

Here's a brief overview of the Pharmacokienetic of some common anticoagulant drugs:

Warfarin:

Absorption: Warfarin is well-absorbed after oral administration.

Distribution: It binds extensively to plasma proteins.

Metabolism: Warfarin are undergoes to hepatic metabolism primarily through the cytochrome P450 system.

Elimination: The drug has a relatively long half-life, and its event can persist for several days. It also mainly excreted through urine out.

Heparin:

Administration: Heparin is usually administered parenterally (intravenous or subcutaneous).

Distribution: It does not bind to plasma proteins and has a short duration of action.

Metabolism: Heparin is not metabolized in the liver. It is cleared by the reticuloendothelial system.

Elimination: The drug has a short half-life and is rapidly eliminated, making it suitable for use in situations requiring quick Anticoagulation.

Direct Oral Anticoagulants (DOACs):

Absorption: DOACs are well-absorbed after oral administration.

Distribution: They have variable protein binding.
Metabolism: DOACs undergo metabolism to some extent, but the majority of the drug is eliminated unchanged or as inactive metabolites.
Elimination**:** The half-life varies among different DOACs, and they are eliminated through renal and/or hepatic pathways.
It's is important to note that individual patient factors, like age, renal function, and concurrent medications, can influence the Pharmacokienetic of anticoagulant drugs. Regular monitoring, dose adjustments, and consideration of drug interactions are crucial aspects of managing patients on anticoagulant therapy to maintain therapeutic efficacy and maintain the risk of the adverse effects of Drug. Always consult an health workers for specific information about anticoagulant drugs and their use in individual cases.
Pharmacokienetic Anticoagulant:
Anticoagulants are Agent that are used for prevent or treat blood clots by interfering with the body's blood clotting mechanisms. The pharmacodynamics of anticoagulants involves their effects on the coagulation cascade, a variety of steps that cause to the formation of blood clots.
There are different classes of anticoagulants, and they may act on different points in the coagulation cascade. Here are some examples of anticoagulant classes and their pharmacodynamics actions:
Vitamin K Antagonists (e.g., Warfarin): These drugs interfere with the synthesis of clotting factors in the liver that require vitamin K. They act on factors II, VII, IX, and X in the coagulation cascade.
Directly Thrombin Inhibitors (e.g., Dabigatran): These drugs directly inhibit the action of the Thrombin, a key enzyme in the coagulation cascade that change fibrinogen to fibrin.
Factor Xa Inhibitors (e.g., Rivaroxaban, Apixaban, Edoxaban): These drugs target factor Xa, another crucial enzyme in the coagulation cascade, inhibiting the conversion of prothrombin to Thrombin.
Heparin (e.g., Unfractionated Heparin, Low Molecular have Weight Heparin): These drugs enhance the activity of Thrombin III, which in turn inhibits several of coagulation factors, particularly Xa and Thrombin.
The pharmacodynamics of anticoagulants involve finding a balance between preventing excessive clotting and avoiding the risk of the bleeding. Monitoring the anticoagulant effect is often necessary, especially with drugs like warfarin, where the international normalized ratio (INR) is frequently checked.
Healthcare providers must consider individual patient characteristics, medical history, and other medications when prescribing anticoagulants, as the risk of bleeding complications must be carefully weighed against the potential benefits of preventing or treating thromboembolic events.

Dosage of Anticoagulant
The dosage of anticoagulants is typically individualized based on factors such as patient's weight, age, kidney function, and the reason for Anticoagulation (e.g Atrial
fibrillation, and deep vein thrombosis, and pulmonary embolism). Monitoring and adjustments by necessary to ensure the medication is effective in preventing blood clots while maintain the risk of the bleeding.
It is have crucial to follow the prescribed dosage and any instructions provided by the healthcare professional. Missing doses or taking too much of the medication can have serious consequences. Regular monitoring through blood tests, such as the international normalized ratio (INR) for warfarin, may be required to assess the effectiveness of the anticoagulant therapy.
If you or someone you know is prescribed anticoagulants, it is essential to communicate openly with the healthcare provider, attend follow-up appointments, and report any signs of bleeding or unusual side effects. Always consult with a Medical professional for personalized advice and guidance from anticoagulant therapy.

Side Effects of Anticoagulants

1. Bleeding
2. Gastrointestinal Issues
3. Hematoma formation
4. Allergic reaction
5. Osteoporosis

Bleeding: Anticoagulants enhance the risk of bleeding. This can manifest as easy bruising, nosebleeds, bleeding gums, or Long period bleeding from minor cuts or injuries. In some cases, internal bleeding can occur, which may be serious and require medical attention.
Gastrointestinal issues: Anticoagulants may cause stomach upset, nausea, or gastrointestinal bleeding. This can lead to symptoms such as abdominal pain, black, tarry stools, or vomiting blood.
Hematoma formation: Anticoagulants may enhance the risk of developing hematoma (collections of blood outside blood vessels) after injury or surgery.

Allergic reactions: Some other individuals peoples may experience allergic reactions to anticoagulant medications, which can include such as rash, itching, swelling, severe dizziness illness, or difficulty breathing. Seek medical attention immediately if any of these symptoms occur.

Osteoporosis: Long-term use of certain anticoagulants, warfarin, associated with bone loss and an enhance risk of osteoporosis.

Hair loss: In rare cases, anticoagulants may contribute to hair loss, although the exact mechanism is not well understood.

Note: It's crucial for individuals taking anticoagulants to follow their healthcare provider's instructions carefully, attend regular check-ups, and report any unusual or side effects promptly. Additionally, patients should inform health workers providers about any other medications, supplements, or herbal products they are taking, as interactions can occur, potentially affecting the effectiveness or safety of anticoagulant therapy. Always consult a health workers for personalized advice and guidance regarding anticoagulant use and potential side effects.

Antiplatelet Medications:

Antiplatelet drugs, such as aspirin or clopidogrel, may be used to prevent of platelets from cleave together and forming clots. These are commonly prescribed to decrease the risk of future strokes.

Pharmacokienetic Antiplatelet:

Pharmacokienetic refers to the study of how the body absorbs, distributes, metabolizes, and excretes drugs. Antiplatelet are substance that inhibit the aggregation of platelets, within the blood cells involved in the formation of the blood clots. These substance are commonly used to prevent and manage cardiovascular diseases.

The Pharmacokienetic of Antiplatelet drugs can very depending on a specific drug. Here are few examples of commonly used Antiplatelet medications and their general Pharmacokienetic characteristics:

Aspirin: Aspirin is an Antiplatelet drug that works by inhibiting the enzyme cyclooxygenase (COX), thereby reducing the production of thromboxane A2, a substance that promotes platelet aggregation. Aspirin is well-absorbed in the stomach and small intestine and undergoes hepatic metabolism.

Clopidogrel: Clopidogrel is another Antiplatelet medication that is a prodrug. It requires activation by the liver to become its active form. The activated form inhibits platelet aggregation by blocking a specific receptor (P2Y12) on the platelet surface. Clopidogrel is metabolized in the liver.

Prasugrel and Ticagrelor: These are also Antiplatelet drugs commonly use for the Treatment of cardiovascular diseases. Prasugrel is a prodrug that undergoes activation in the body, while Ticagrelor is directly active. Both drugs are affect platelet function by inhibiting the P2Y12 receptor. They have different Pharmacokienetic profiles.

It's also important to note that individual patient have different factors, such as age, liver function, and concurrent medications, can influence the Pharmacokienetic of Antiplatelet drugs. Therefore, healthcare providers consider these factors when prescribing and monitoring Antiplatelet therapy. If you have some important Idea about a particular Antiplatelet medication, it's recommended to consult with a health workers or personalized information.

Pharmacokienetic Antiplatelet:

Antiplatelet drugs are medications that involve with the normal function of the platelets, within a blood cells involved in the formation of blood clots. These substance are commonly to prevent or treat abnormal blood clotting, such as cardiovascular diseases. The pharmacodynamics effects of Antiplatelet drugs are related to their action to inhibit platelet function and prevent the formation of a blood clots.

Some commonly used Antiplatelet Agent and their pharmacodynamics mechanisms include:

Aspirin (Acetylsalicylic acid): Aspirin irreversibly inhibits the enzyme cyclooxygenase (COX), is responsible for the synthesis of prostaglandins. Prostaglandins play role in the platelet activation and aggregation. By inhibiting COX, aspirin decrease the formation of thromboxane A2, a potent platelet aggregator, leading to decreased platelet activation and aggregation.

Clopidogrel (Plavix): Clopidogrel is a thienopyridine derivative that inhibits the P2Y12 adenosine diphosphate (ADP) receptor on the platelet surface. ADP is a potent stimulate of platelet aggregation, and by blocking its receptor, clopidogrel prevents platelet activation and aggregation.

Prasugrel (Efficient): Similar to clopidogrel, Prasugrel is a thienopyridine Antiplatelet drug that inhibits the P2Y12 ADP receptor. is used for prevent blood clot formation in patients with acute coronary syndromes.

Ticagrelor (Brilinta): Ticagrelor is an reversible that inhibitor the P2Y12 ADP receptor. It differs from clopidogrel and Prasugrel does not require metabolic activation, and its is effects also rapidly reversible upon discontinuation.

Dipyridamole: Dipyridamole inhibits platelet aggregation by increasing the levels of adenosine, which has Antiplatelet properties. It also has vasodilatory effects.
Glycoprotein IIb/IIIa Inhibitors (e.g., abciximab, eptifibatide, tirofiban): These drugs target the glycoprotein IIb/III receptor on the platelet surface, preventing the final common pathway of platelet aggregation.
The pharmacodynamics actions of these Antiplatelet drugs collectively contribute to prevention of thrombus formation and decrease risk of cardiovascular events, such as heart attacks and strokes. is important to note that the use of these medications should be carefully managed under the guidance of healthcare professionals, as they can enhance the risk of bleeding.

Side Effect Antiplatelet

i. Bleeding
ii. Gastrointestinal Issues
iii. Allergic reaction
iv. Hematological Effects
v. Liver Function
vi. Tinnitus(Ringing in the Ears)

Bleeding: The most significant side effect of Antiplatelet drugs is an enhanced risk of bleeding. This can manifest as easy bruising, nosebleeds, gastrointestinal bleeding, or, in rare cases, more severe bleeding events.
Gastrointestinal Issues: Some Antiplatelet drugs may irritate the stomach lining, leading to gastrointestinal discomfort, nausea, or abdominal pain.
Allergic Reactions: In rare cases, different peoples are experience allergic reactions to Antiplatelet medications, which can include as rash, itching, swelling, and difficulty breathing.
Hematological Effects: Antiplatelet drugs can affect blood cell counts. For example, may decrease the number of white blood cells or platelets, leading to conditions such as leukopenia or thrombocytopenia.
Liver Function: Certain Antiplatelet medications may affect liver function, leading to changes in liver enzyme levels. Regular monitoring of liver function may be necessary in some cases.
Tinnitus (Ringing in the Ears): Some different may experience tinnitus as an side effect of Antiplatelet medications.
Note: It's important for individuals taking Antiplatelet medications to be aware of these some of further side effects and to promptly report any unusual symptoms to their healthcare provider. Additionally, healthcare providers carefully observe the risks and also benefits of Antiplatelet Drugs for each patient based on their medical history, overall health, and other factors. Always consult with a Health workers for personalized advice regarding medication use and potential side effects.
Thrombolytic Therapy (Clot-busting Medications):
Thrombolytic drugs, such as alteplase (tPA), can be administered intravenously to dissolve blood clots. However, these Agent are usually used within a specific time window after the onset of symptoms, and they may not be suitable for all patients.

Surgery or Interventional Procedures:

In some cases, procedures such as thrombectomy or embolectomy may be performed to physically remove the blood clot from the affected blood vessel. This is often considered in cases of large vessel occlusion.
Management of Underlying Heart Conditions:
Addressing the underlying heart condition that led by the formation of blood clot is crucial. This may involve medications or procedures to manage conditions like atrial fibrillation, heart valve disorders, or other cardiac abnormalities.
Rehabilitation and Supportive Care:
Stroke rehabilitation is an essential ways for patients recovering from a cardiac embolism stroke. Physical therapy, occupational therapy, and speech therapy may be recommended to improve motor skills, functional independence, and communication abilities.
It's important to note that are specific treatment plan may usually depending on individual patient characteristics, the severity of the stroke, and other health factors. Early intervention is crucial, so if someone is experiencing symptoms of a stroke, it's important to seek emergency medical attention immediately. Stroke treatment is time-sensitive, and the effectiveness of certain interventions may be limited by quickly they are administered after the onset of symptoms. Always consult with health workers for personalized advice and treatment options.

Physiotherapy:

Physiotherapy must Important by rehabilitation of individuals who have experienced a cardiac embolism stroke. Cardiac embolism strokes occur when a blood clot and other debris forms from the heart and travels

to brain, caused a blockage in a blood vessels. The aftermath of a stroke often leads to physical impairments and functional limitations can be addressed through physiotherapy. Here are some aspects of physiotherapy for individuals recovering from a cardiac embolism stroke:

a. Assessment
b. Mobility and Range of Motion Exercises
c. Strength Training
d. Gait Training
e. Functional Activities
f. Neuromuslar Re-education
g. Education and Home Exercise Programs
h. Psychosocial Support

Assessment and Goal Setting:A comprehensive assessment is conducted to understand the individual's physical abilities, limitations, and overall health.
Goal-setting involves establishing realistic and achievable targets for recovery.
Mobility Exercises: Physiotherapists work on improving joint mobility in affected limbs. Gentle exercises are introduced to prevent contractures and maintain flexibility.
Strength Training: Progressive resistance exercises are implemented to improve muscle strength.
Emphasis on both upper and lower limb strength helps individuals regain functional independence.
Coordination Training: Specific exercises that designed to enhancebalance and coordination, decrease the risk of falls.
Proprioceptive and balance drills may be incorporated to improve spatial awareness.
Gait Training: Gait training focuses on restoring a normal walking pattern.
Assistance devices, such as walkers or canes, may be used initially and gradually phased out as the individual gains stability. Cardiovascular Conditioning:
Gradual introduction of cardiovascular exercises to improve overall fitness.
Individualized programs to increase endurance and stamina.
Functional Activities: Therapy includes practicing daily activities (e.g., dressing, bathing, cooking) to enhance independence.
Task-specific training is crucial for transferring therapy gains to real-world scenarios.
Neuromuslar Re-education: Techniques to retrain muscles and restore normal movement patterns.Visual and Proprioceptive feedback may be used to enhance motor learning.
Education and Home Exercise Programs: Providing education on stroke recovery and strategies to manage symptoms.
Developing a home exercise program to encourage ongoing rehabilitation.
Psychosocial Support: Recognizing the psychological impact of stroke and incorporating strategies to support emotional well-being.
Encouraging participation in support groups or counseling when needed.
Note: It's essential to note that the physiotherapy approach should be individualized, taking into account the specific needs and abilities of each stroke survivor. Regular reassessment and modification of the rehabilitation plan are crucial for optimal recovery. Additionally, collaboration with some medical professionals, such as occupational therapists and speech therapists, may be necessary for a comprehensive stroke rehabilitation program

Case of study

Patient Information:
Pateint Number 1
Age: 65 years
Gender: Male
Medical History: Hypertension, hyperlipidemia, and type 2 diabetes.
Social History: Non-smoker, occasional alcohol consumption.
Family History: Father had a history of stroke.
Presenting Complaint:
Pateint brought to the emergency room by his wife after suddenly experiencing the following symptoms:
Sudden onset of confusion
Difficulty speaking and slurred speech
Weakness in the right arm and leg
Loss of balance and coordination
Timeline of Events:

8:30 AM: Pateint 1 was at home when his wife noticed sudden confusion and slurred speech.
8:35 AM: Weakness in the right arm and leg became apparent, and he struggled to maintain balance.
8:40 AM: Emergency medical services (EMS) were called, and Mr. Smith was brought to the hospital.
Clinical Examination:
Neurological Examination
Glasgow Coma Scale (GCS): 14/15
NIH Stroke Scale: 12 (indicating moderate stroke severity)
Right-sided weakness and decreased sensation.
Slurred speech and difficulty finding words.
Vital Signs:
Blood Pressure: 169/93 mm Hg
Heart Rate: 85 bpm
Respiratory Rate: 18/min
Oxygen Saturation: 99% on room air
Laboratory Investigations:
Complete Blood Count (CBC): Within normal limits
Blood Glucose: 180 mg/d L
Lipid Profile: Elevated LDL cholesterol
ECG: Normal sinus rhythm
Imaging Studies:
Non-contrast CT scan of the brain: Confirmed a left middle cerebral artery infarct.
Diagnosis:
Cardiac embolism stroke due to atrial fibrillation.
Further Investigations:
ECG: Revealed atrial fibrillation.
Electrocardiography: Show the available of clot in the left atrial appendage.
Treatment:
Immediate: Administered tissue plasminogen activator (tPA) within the recommended time window.
Anticoagulation: Started on intravenous heparin followed by oral anticoagulant (warfarin).
Blood Pressure Management: Initiated antihypertensive medications.
Rehabilitation: Physical and speech therapy to aid recovery.
Outcome:
Pateint Number 1 showed gradual improvement in motor function and speech with rehabilitation. He was discharged with a plan for long-term Anticoagulation therapy and close follow-up with a neurologist and cardiologist.

Certainly, here's a hypothetical case study of a cardiac embolism stroke in a 75-year-old individual:
Patient Information:
Pateint Number 2
Age: 75 years
Gender: Female
Medical History: Hypertension, Hyperlipidemia, Atrial Fibrillation
Presenting Complaint:
Pateint was brought to the emergency department by his family after suddenly experiencing weakness from the left side of his body, slurred speech, and difficulty understanding spoken language. The symptoms started approximately 1 hours before arrival at the hospital.
Clinical Examination:
Upon examination, Pateint presented with facial droop from the left side, weakness in a left arm and leg, and difficulty with coordination. His blood pressure has elevated at 180/95 mm Hg, and he had an irregular pulse.
Diagnostic Workup:
Imaging: A non-contrast CT scan of the head was performed to rule out hemorrhagic stroke, and it revealed no evidence of bleeding.
Brain Imaging: Subsequent imaging with MRI confirmed the presence of an ischemic stroke in the right between cerebral artery territory.

Cardiac Workup: Given the patient's age and symptoms, more investigation will be carried out to observe the cardiac source of embolism. An Echo cardiogram showed the presence of atrial fibrillation, a common risk factor for embolism strokes.
Laboratory Investigations:
Blood tests were conducted to assess the patient's coagulation profile, lipid levels, and other relevant parameters. The results indicated elevated levels of LDL cholesterol and abnormalities in the coagulation cascade.
Treatment and Management:
Intravenous Thrombolysis: As the patient presented within the therapeutic window, he received intravenous alteplase to dissolve the clot causing the ischemic stroke.
Anticoagulation Therapy: Given the diagnosis of atrial fibrillation, the patient was started on Anticoagulation therapy (e.g., warfarin or direct oral anticoagulants) to prevent further embolism events.
Blood Pressure Management: Blood pressure was carefully managed to ensure optimal control, reducing the risk of recurrent strokes.
Rehabilitation: Physical and occupational therapy were initiated to assist in the recovery of motor and cognitive functions.
Follow-up:
has monitored closely during his hospital stay, and a multidisciplinary team including neurologists and cardiologists collaborated in his care. The patient was discharged with a plan for outpatient rehabilitation and continued management of his underlying conditions.
This case study illustrates a common scenario where atrial fibrillation contributes to a cardiac embolism stroke in an elderly individual, highlighting the importance of prompt diagnosis, appropriate treatment, and comprehensive post-stroke care.
Patient Information:
Pateint Number 3
Age: 45 years
Gender: Male
Medical History: No significant medical history, occasional smoking, and moderate alcohol consumption.
Presenting Complaint:
Pateint was brought to the emergency department by his family after suddenly experiencing weakness on the right side of his body and difficulty speaking. The symptoms appeared abruptly while he was at work, prompting immediate concern.
Clinical Presentation:
Time of Onset: Approximately 2 hours before arrival at the hospital.
Neurological Examination: Weakness in the right arm and leg, facial droop on the right side, and slurred speech.
NIH Stroke Scale Score: 14 (indicating a moderate to severe stroke).
Diagnostic Workup:
CT Scan: Done to rule out hemorrhagic stroke. Results showed no hemorrhage.
MRI: Confirmed the presence of the ischemic stroke in the left between cerebral artery territory.
Echo cardiogram: Revealed a Cardio embolism source with a clot in the left atrium, suggesting a potential origin for the embolus causing the stroke.
Cardiac Assessment:
EKG (Electrocardiogram): Showed normal sinus rhythm.
Holter Monitor: Ordered to assess for any underlying arrhythmia.
Trans esophageal Echo cardiogram (TEE): Detected a clot in the left atrium, likely due to atrial fibrillation.
Treatment and Management:
Immediate Stroke Management:
IV Alteplase (tPA): Administered within the recommended time window for thrombolysis.
Supportive care: Blood pressure and glucose management, monitoring for complications.
Secondary Stroke Prevention:
Anticoagulation: Started on anticoagulant therapy (e.g., warfarin or a direct oral anticoagulant) to prevent further embolism events.
Rehabilitation: Initiated physical therapy, occupational therapy, and speech therapy for recovery.
Cardiac Management:
Cardiology Consult: Collaborated with cardiology for further management of atrial fibrillation.
Anticoagulation Management: Adjusted Anticoagulation therapy based on TEE findings.

Follow-up:
Pateint has monitored closely for any recurrent strokes or bleeding complications.
Regular follow-up appointments with neurology and cardiology for ongoing management.
Prognosis:
The patient showed continue improvement with rehabilitation and responded well to Anticoagulation therapy. Long-term monitoring for recurrent strokes and cardiac issues was recommended.
This case study is a general illustration, and the actual management would depend on a specific circumstances and medical guidelines at the period of the incident. Always consult Medical professionals for accurate information and advice.
Pateint Information
Pateint Number 4
Age: 58 years
Gender: Male
Medical History: Hypertension, Hyperlipidemia
Social History: Non-smoker, occasional alcohol consumption, sedentary lifestyle
Presenting Complaint:
Pateint was brought to the emergency room by his family after suddenly experiencing weakness from the left side of his body, difficulty speaking, and confusion. The symptoms started approximately 2 hours before arrival.
Initial Assessment:
Vital Signs: Blood pressure elevated (160/90 mm Hg), heart rate increased (90 bpm), normal respiratory rate, and temperature.
Neurological Examination: Left-sided weakness, facial droop, slurred speech, and difficulty understanding and responding appropriately to questions.
Diagnostic Workup:CT Scan: To rule out hemorrhagic stroke, a non-contrast CT scan of the brain was performed, revealing no bleeding.
CT Angiography (CTA) or Magnetic Resonance Angiography (MRA): To assess blood vessels and identify any blockages or abnormalities.
Blood Tests: Routine blood tests to assess glucose levels, lipid profile, and coagulation status.
Electrocardiogram (ECG or EKG): To evaluate the heart's electrical activity and identify any irregularities.
Echo cardiogram: To observe the anatomical and physiological of the heart, specifically looking for sources of potential embolism, such as blood clots in the heart chambers.
Diagnosis:
The diagnostic workup revealed a cardiac embolism stroke, indicating that a blood clot originating from the heart had traveled to the brain, causing the stroke. The echo cardiogram showed a clot from the left atrial appendage, and the patient has diagnosed with atrial fibrillation (AF), a condition that enhance risk of blood clots forming in the heart.
Treatment:
Immediate Treatment: Mr. Johnson received intravenous thrombolytic therapy (such as alteplase) to dissolve the clot and improve blood flow to the affected area of the brain.
Secondary Prevention: Anticoagulant medications (e.g., warfarin or direct oral anticoagulants) were initiated to prevent further blood clot formation.
Blood Pressure Management: Medications were prescribed to control blood pressure.
Physical and Occupational Therapy: Rehabilitation services were initiated to help improve motor and cognitive functions.
Follow-up:
Pateint was closely monitored in the hospital, and his condition Continues improved with rehabilitation. He was educated about the importance of medication adherence, lifestyle modifications (such as diet and exercise), and regular follow-up appointments with both neurology and cardiology specialists.
It's crucial to remember that this is a hypothetical case, and al-life can vary significantly.Situation Always consult with a Medical professionals for accurate information and advice tailored to individual circumstances.
Pateint Information
Pateint Number 5
Age: 55
Occupation: Accountant
Medical History: Hypertension, Hyperlipidemia

Social History: Married with two children, non-smoker, occasional social drinker
Presenting Complaint:
Pateint was brought to the emergency department by her husband, who noticed sudden onset weakness on the right side of her body and slurred speech. The symptoms started approximately two hours ago.
Clinical Presentation:
Neurological Examination:
Right-sided weakness, more pronounced in the arm than in the leg
Facial droop on the right side
Difficulty speaking and forming coherent sentences
Decreased sensation on the right side
Vital Signs:
Blood Pressure: 162/90 mm Hg
Heart Rate: 78 bpm
Respiratory Rate: 18 breaths/min
Oxygen Saturation: 97% on room air
Diagnostic Tests:
CT Scan of the Head:
Revealed a left between cerebral artery ischemic stroke with no evidence of hemorrhage.
Electrocardiography:
Showed a large mobile thrombus in the left atrial appendage, suggesting a cardiac source for embolism.
Blood Tests:
Elevated cholesterol levels
Normal blood glucose levels
Normal complete blood count
Management:
Immediate Treatment:
Administered intravenous tissue plasminogen activator (tPA) within the therapeutic window.
Initiated Antiplatelet therapy with aspirin.
Blood pressure management with antihypertensive medications.
Secondary Prevention:
Started on stating therapy for hyperlipidemia.
Cardiology consultation for consideration of Anticoagulation therapy due to the cardiac source of embolism.
Rehabilitation:
Physiotherapy, occupational therapy, and speech therapy initiated to improve motor function, daily activities, and speech.
Follow-up:
Pateint showed gradual improvement in her neurological deficits during the hospital stay.
Discharged with a comprehensive plan for rehabilitation, including outpatient physical and speech therapy.
Scheduled for close follow-ups with neurology and cardiology to monitor progress and adjust medications.
This case illustrates the importance of prompt recognition and management of a cardiac embolism stroke, involving for multidisciplinary approached of the optimal patient outcomes.

CHAPTER 5

Control Of Cardiac Embolic Stroke

i. Anticoagulants Medication
ii. Direct Oral Anticoagulants
iii. Lifestyle Modification
iv. Regular monitoring
v. Blood pressure Management
vi. Diabetes Management
vii. Cholesterol Control

Controlling cardiac embolism stroke involves managing the underlying conditions that enhance the risk of embolism (blood clots) forming from the heart and subsequently traveling to brain. The major common cause of cardiac embolism stroke is atrial fibrillation (AF), a heart rhythm that can lead to the formation of blood clots in the atria (upper chambers of the heart). Here is key strategies of controlling cardiac embolism stroke:

Anticoagulant Medications: Warfarin: This traditional oral anticoagulant been used widely, but it requires regular monitoring of the International Normalized Ratio (INR) and adjustments to maintain the appropriate level of Anticoagulation.

Direct Oral Anticoagulants (DOACs): Drugs such as dabigatran, rivaroxaban, apixaban, and Edoxaban are newer anticoagulants that are as effective as warfarin and generally do not require regular monitoring.

Rate or Rhythm Control for Atrial Fibrillation: Controlling the heart rate or rhythm in patients with have atrial fibrillation is important to decrease the risk of blood clots.

Medications like beta-blockers, calcium channel blockers, or arrhythmia may be prescribed.

Cardioversion: In some cases, restoring normal heart rhythm through electrical Cardioversion or pharmacological methods may be necessary.

Left Atrial Appendage Closure: The left atrial appendage is an common site form blood clot formation in patients with AF. Closing this appendage surgically or through minimally invasive procedures can be decease the risk of embolism stroke.

Lifestyle Modifications: Lifestyle changes such as maintaining a healthy diet, regular exercise, and avoiding smoking contribute to overall cardiovascular health also decrease risk of stroke.

Regular Monitoring: Patients at risk for embolism stroke, especially those who have AF, should have regular follow-up appointments with healthcare providers to monitor their condition and adjust treatment as needed.

Blood Pressure Management: Controlling hypertension is crucial in preventing stroke. Medications, lifestyle changes, and regular monitoring it also help maintain optimal blood pressure levels.

Diabetes Management: Effective management of diabetes is important, as uncontrolled diabetes can enhance the risk of cardiovascular complications, including stroke.

Cholesterol Control: Managing cholesterol levels through lifestyle changes and medication can contribute to overall cardiovascular health.

Individuals at risk of cardiac embolism stroke need to work closely with the professional healthcare providers to develop a personalized treatment plan tailored to their specific medical conditions and risk factors. Treatment decisions will depend on the underlying causes and individual patient characteristics.

Prevention of Cardiac Embolic Stroke

Cardiac embolism strokes occur when a blood clot forms in a heart and then travels to brain, causing a blockage in a blood vessel. Prevention of cardiac embolism strokes involves managing the underlying conditions that can contribute to clot formation from the heart. Here are some key strategies:

1. Anticoagulant Medication
2. Management Atrial Fibrillation(AFib)
3. Hypertension Management
4. Management of Heart Valve Disorder
5. Lifestyle Modification
6. Healthy Diet
7. Regular Exercise
8. Regular Medical Checkups
9. Smoking Cessation
10. Limiting Alcohol Intake

Anticoagulant Medications: Prescription Anticoagulants (Blood Thinners): Medications such as Warfarin, dabigatran, rivaroxaban, and apixaban is an prescribed to prevent blood clots forming from the heart and reduce the risk of stroke.

Antiplatelet Medications: Aspirin: Aspirin is an Antiplatelet medication that may be recommended for prevent blood clot formation. It is works by inhibiting platelet aggregation, reducing the likelihood of clot formation.

Management of Atrial Fibrillation (AFib): Control of Heart Rhythm: For individuals patient with atrial fibrillation (irregular heart rhythm can be lead to clot formation), medications may be prescribed to control the heart rhythm.

Anticoagulation for AFib: Individuals with AFib are often prescribed anticoagulant medications to prevent clot formation in the heart.

Treatment of Cardiovascular Conditions: Hypertension Management: Controlling high blood pressure is crucial in preventing cardiac embolism strokes. Lifestyle changes and medications may be recommended.

Management of Heart Valve Disorders: People with heart valve disorders may need anticoagulant therapy or other treatments to prevent clot formation.

Lifestyle Modifications: Healthy Diet: Adopting of diet more e.g fruits, vegetables, whole grains, and lean proteins can contribute to heart health.

Regular Exercise: Physical excesses can help maintain a healthy cardiovascular system and decrease the risk of clot formation.

Regular Medical Checkups: Regular monitoring of cardiovascular health and addressing any risk factors or underlying conditions is essential for stroke prevention.

Smoking Cessation: Smoking increases the risk of blood clots and cardiovascular diseases. Quitting smoking is a crucial step in preventing cardiac embolism strokes.

Limiting Alcohol Intake: Excessive alcohol consumption can contribute to high blood pressure and enhance the risk of stroke. It's is Important to note that the specific prevention strategies may vary based on an individual's medical history, risk factors, and overall health System. Consultation a Medical healthcare professional is essential for personalized advice and guidance on stroke prevention.

Conclusion

Preventing cardiac embolism strokes involves of comprehensive approach includes managing underlying cardiac conditions, utilizing appropriate medications, and adopting a healthy lifestyle. Individualized care plans, in consultation with healthcare professionals, are essential to address the unique risk factors of each patient. Regular monitoring and timely adjustments to the treatment plan contribute to the overall success of preventing cardiac embolism strokes. Patient education is crucial for promoting adherence to medications, lifestyle modifications, and follow-up appointments.

Reference

1. Tan, S.M., Ho, J.S., Sia, C.H., Leow, A.S., Seet, R.C., Teoh, H.L., Yuen, L.Z., Tham, C.H., Chua, C.Y., Yap, E.S. and Chan, B.P., 2023. Etiologies, mechanisms, and risk factors of ischemic stroke in a young Asian adult cohort. *Journal of Stroke and Cerebrovascular Diseases*, *32*(8), p.107134.

2. Field, T.S., Sposato, L.A., Hill, M.D., Healey, J.S., Andrade, J.G. and Zhou, L.W., 2023. Embolic stroke of undetermined source: current perspectives on diagnosis, investigations, and management. Canadian Journal of Cardiology, 39(2), pp.172-186.

3. Chaudhari, R., Parikh, A., Dalal, Y., Desai, D. and Parikh, A., 2023. Risk Factor Profile in Different Subtypes of Acute Ischemic Stroke: A Prospective Observational Study. medRxiv, pp.2023-11.

4. Hoh, B.L., Ko, N.U., Amin-Hanjani, S., Chou, S.H.Y., Cruz-Flores, S., Dangayach, N.S., Derdeyn, C.P., Du, R., Hänggi, D., Hetts, S.W. and Ifejika, N.L., 2023. 2023 guideline for the management of patients with aneurysmal Subarachnoid hemorrhage: a guideline from the American Heart Association/American Stroke Association. Stroke, 54(7), pp.e314-e370.

5. Johansen, M.C., 2023. The Future of Ischemic Stroke Diagnosis and a Review of Underrecognized Ischemic Stroke Etiologies. *Neurotherapeutics*, pp.1-11.

6. Bersano, A. and Gatti, L., 2023. Pathophysiology and Treatment of Stroke: Present Status and Future Perspectives. *International Journal of Molecular Sciences*, *24*(19), p.14848.

7. Gurkas, E., AKPINAR, C., Ozdemir, A.O., Aykac, O. and Önalan, A., 2023. Is cardioembolic stroke more frequent than expected in acute ischemic stroke due to large vessel occlusion? *European Review for Medical & Pharmacological Sciences*, *27*(9).

8. Fan, J., Li, X., Yu, X., Liu, Z., Jiang, Y., Fang, Y., Zong, M., Suo, C., Man, Q. and Xiong, L., 2023. Global burden, risk factor analysis, and prediction study of ischemic stroke, 1990–2030. *Neurology*, *101*(2), pp.e137-e150.
9. Masood, S., Ashraf, S.M.K., Malik, M.A. and Wahab, S., 2023. P-wave indices and left atrial mechanics as predictors of atrial cardiomyopathy in embolism stroke of undetermined source. *Scientific Reports*, *13*(1), p.19965.
10. Qiao, M.L., Ma, L., Wang, C.B., Fang, L.B., Fan, Z.X., Niu, T.T., Wang, Z.Y., Lu, J.F., Yuan, B.Y. and Liu, G.Z., 2023. Clinical features, risk factors and survival in cardiac myxoma-related ischemic stroke: A multicenter case-control study. Journal of the Neurological Sciences, 444, p.120517.
11. Bukhari, S., Yaghi, S. and Bashir, Z., 2023. Stroke in Young Adults. *Journal of Clinical Medicine*, *12*(15), p.4999.
12. Osteraas, N.D. and Dafer, R.M., 2023. Advances in Management of the Stroke Etiology One-Percenters. Current Neurology and Neuroscience Reports, pp.1-25.
13. Larson, S.T., Ray, B.E. and Wilbur, J., 2023. Ischemic Stroke Management: Post hospitalization and Transition of Care. American Family Physician, 108(1), pp.70-77.
14. von Falkenhausen, A.S., Feil, K., Sinner, M.F., Schönecker, S., Müller, J., Wischmann, J., Eiffener, E., Clauss, S., Poli, S., Poli, K. and Zuern, C.S., 2023. Atrial Fibrillation Risk Assessment after Embolic Stroke of Undetermined Source. Annals of Neurology, 93(3), pp.479-488.
15. Alshukri, A., Nadar, S.K., Gujjar, A.R., Al Lawati, H., Al-Rawahi, M., Al-Kindi, I. and AlFarsi, M., 2023. Yield of Cardiac Investigations in Patients Presenting with Acute Ischaemic Stroke: A Single Tertiary Centre Experience. *Sultan Qaboos University Medical Journal*, *23*(3), p.351.
16. Shehjar, F., Maktabi, B., Rahman, Z.A., Bahader, G.A., James, A.W., Naqvi, A., Mahajan, R. and Shah, Z.A., 2023. Stroke: Molecular mechanisms and therapies: Update on recent developments. Neurochemistry International, 162, p.105458.
17. Mele, F., Scopelliti, G., Manini, A., Ferrari Aggradi, C., Baiardo, M., Schiavone, M., Viecca, M., Ianniello, A., Bertora, P., Forleo, G.B. and Pantoni, L., 2023. Etiologic reclassification of cryptogenic stroke after implantable cardiac monitoring and computed tomography angiography re-assessment. Journal of Neurology, 270(1), pp.377-385.
18. Hindsholm, M.F., Damgaard, D., Gurol, M.E., Gaist, D. and Simonsen, C.Z., 2023. Management and Prognosis of Acute Stroke in Atrial Fibrillation. Journal of Clinical Medicine, 12(17), p.5752.
19. Uhe, T., Wasser, K., Weber-Krüger, M., Schäbitz, W.R., Köhrmann, M., Brachmann, J., Laufs, U., Dichgans, M., Gelbrich, G., Petroff, D. and Prettin, C., 2023. Intensive heart rhythm monitoring to decrease ischemic stroke and systemic embolism—the Find-AF 2 study—rationale and design. *American Heart Journal*, *265*, pp.66-76.
20. Yoshihara, S., 2023. Evaluation of causal heart diseases in cardioembolic stroke by cardiac computed tomography. *World Journal of Radiology*, *15*(4), p.98.Addisu, Z.D. and Mega, T.A., 2023. Clinical Characteristics and Treatment Outcomes of Acute Ischemic Stroke with Atrial Fibrillation Among Patients Admitted to Tertiary Care Hospitals in Amhara Regional State: Retrospective-Cohort Study. Vascular Health and Risk Management, pp.837-853.
21. Kitazono, T., Kamouchi, M., Matsumaru, Y., Nakamura, M., Umemura, K., Matsuo, H., Koyama, N., Tsutsumi, J. and Kimura, K., 2023. Efficacy and safety of prasugrel vs clopidogrel in thrombotic stroke patients with risk factors for ischemic stroke recurrence: a double-blind, phase III study (prastro-III). Journal of atherosclerosis and thrombosis, 30(3), pp.222-236.
22. Mac Grory, B., Flood, S.P., Apostolidou, E. and Yaghi, S., 2019. Cryptogenic stroke: diagnostic workup and management. Current treatment options in cardiovascular medicine, 21, pp.1-19.
23. Sambola, A., Lozano-Torres, J., Boersma, E., Olmos, C., Ternacle, J., Calvo, F., Tribouilloy, C., Reskovic-Luksic, V., Separovic-Hanzevacki, J., Park, S.W. and Bekkers, S., 2023. Predictors of embolism and death in left-sided infective endocarditis: the European Society of Cardiology EURObservational Research Programme European Infective Endocarditis registry. European Heart Journal, 44(43), pp.4566-4575.
24. Usman, R., Gulzar, W., Ajmal, K., Hashim, H., Altaf, S. and Shuaib, M., 2023. Comparison of the impact of rivaroxaban against aspirin on stroke recurrence in patients having a history of atrial cardiomyopathy and unknown stroke. *J Ayub Med Coll Abbottabad*, *35*(1), pp.120-4.
25. Noubiap Nzeale, J.J., 2023. *Screening, risk stratification, and management of atrial fibrillation* (Doctoral dissertation).
26. Costamagna, G., Navi, B.B., Beyeler, M., Hottinger, A.F., Alberio, L. and Michel, P., 2023, July. Ischemic stroke in cancer: mechanisms, biomarkers, and implications for treatment. In *Seminars in*

thrombosis and hemostasis. 333 Seventh Avenue, 18th Floor, New York, NY 10001, USA: Thieme Medical Publishers, Inc.
27. Badescu, M.C., Sorodoc, V., Lionte, C., Ouatu, A., Haliga, R.E., Costache, A.D., Buliga-Finis, O.N., Simon, I., Sorodoc, L., Costache, I.I. and Rezus, C., 2023. Direct Oral Anticoagulants for Stroke and Systemic Embolism Prevention in Patients with Left Ventricular Thrombus. *Journal of Personalized Medicine*, *13*(1), p.158.
28. Saceleanu, V.M., Toader, C., Ples, H., Covache-Busuioc, R.A., Costin, H.P., Bratu, B.G., Dumitrascu, D.I., Bordeianu, A., Corlatescu, A.D. and Ciurea, A.V., 2023. Integrative approaches in acute ischemic stroke: from symptom recognition to future innovations. *Biomedicines*, *11*(10), p.2617.
29. Kurisu, K., Uchida, K., Okuyama, T., Miyata, K., Yamaguchi, Y., Ajiki, M., Takada, T., Hokari, M., Asaoka, K., Itamoto, K. and Fujimura, M., 2023. Clinical characteristics of endovascular treatment for acute ischemic stroke with atherosclerotic etiology: Factors associating its clinical outcome. *Clinical Neurology and Neurosurgery*, *228*, p.107680.
30. Choi, Y., Kim, Y., Kim, S.E. and Lee, J.H., 2023. Association of non-sustained atrial tachycardia and its duration in 24-hour Holter monitoring with embolic stroke of unknown source. *Journal of the Neurological Sciences*, *447*, p.120610.
31. Fraser, S., Pabst, L. and Smith, F., 2023. Stroke in the young. *Current Opinion in Neurology*, *36*(2), pp.131-139.
32. Rong, B., Guo, Z., Gao, L., Yang, Y., Zi, W., Qiu, Z., Li, F., Lv, Z., Luo, Y., Meng, R. and Xie, Y., 2023. Association of tirofiban treatment with outcomes following endovascular therapy in cardioembolic stroke: insights from the RESCUE BT randomized trial. *European Journal of Medical Research*, *28*(1), p.473.
33. Katsi, V., Georgiopoulos, G., Skafida, A., Oikonomou, D., Klettas, D., Vemmos, K. and Tousoulis, D., 2019. Noncardioembolic stroke in patients with atrial fibrillation. Angiology, 70(4), pp.299-304.
34. Fonseca, A.C., 2023. Stroke and Recent Myocardial Infarction, Reduced Left Ventricular Ejection Fraction, Left Ventricular Thrombus, and Wall Motion Abnormalities. *Current Cardiology Reports*, pp.1-11.
35. Colombo, P.C., Ibeh, C., Melmed, K.R. and Willey, J., 2023. Neurologic Complications: Pathophysiology, Incidence, Types, Prevention, and Management. Textbook of Transplantation and Mechanical Support for End-Stage Heart and Lung Disease, pp.945-965.
36. Xing, L.Y., Diederichsen, S.Z., Højberg, S., Krieger, D.W., Graff, C., Olesen, M.S., Brandes, A., Køber, L., Haugan, K.J. and Svendsen, J.H., 2023. Screening for atrial fibrillation to prevent stroke in elderly individuals with or without preexisting cardiovascular disease: A post hoc analysis of the randomized LOOP Study. *International Journal of Cardiology*, *370*, pp.197-203.
37. Small, C., Mehkri, Y., Panther, E., Felisma, P. and Lucke-Wold, B., 2023. Coronavirus disease-2019 and stroke: Pathophysiology and management. *Canadian Journal of Neurological Sciences*, *50*(4), pp.495-502.Diener, H.C., Easton, J.D., Hart, R.G., Kasner, S., Kamel, H. and Ntaios, G., 2022. Review and update of the concept of embolic stroke of undetermined source. *Nature Reviews Neurology*, *18*(8), pp.455-465.Caplan, L.R., Kasner, S.E. and Dashe, J.F., 2022. Stroke: Etiology, classification, and epidemiology. *UpToDate. Ted W Post (ed): UpToDate, Waltham, Massachusetts*.
38. Caplan, L.R., Kasner, S.E. and Dashe, J.F., 2022. Stroke: Etiology, classification, and epidemiology. *UpToDate. Ted W Post (ed): UpToDate, Waltham, Massachusetts*.
39. Sener, U. and Keser, Z., 2022, November. Ischemic stroke in patients with malignancy. In *Mayo Clinic Proceedings* (Vol. 97, No. 11, pp. 2139-2144). Elsevier.
40. Jannati, M., 2024. Risk factors for stroke post coronary artery bypass graft surgery: A review of literature. *Medicina Clínica Práctica*, *7*(1), p.100405.
41. Joglar, J.A., Chung, M.K., Armbruster, A.L., Benjamin, E.J., Chyou, J.Y., Cronin, E.M., Deswal, A., Eckhardt, L.L., Goldberger, Z.D., Gopinathannair, R. and Gorenek, B., 2024. 2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *Circulation*, *149*(1), pp.e1-e156.
42. Smith, E.E., Yaghi, S., Sposato, L.A. and Fisher, M., 2024. Atrial Fibrillation Detection and Load: Knowledge Gaps Related to Stroke Prevention. *Stroke*, *55*(1), pp.205-213.
43. Kotadia, I.D., O'Dowling, R., Aboagye, A., Crawley, R.J., Bodagh, N., Gharaviri, A., O'Hare, D., Solis-Lemus, J.A., Roney, C.H., Sim, I. and Ramsey, D., 2024. High Prevalence of New Clinically Significant Findings in Patients With Embolic Stroke of Unknown Source Evaluated by Cardiac Magnetic Resonance Imaging. Journal of the American Heart Association, p.e031489.

44. Lee, P., Dhillon, G., Pourafkari, M., DaBreo, D., Jaff, Z., Appireddy, R., Jin, A., Boissé Lomax, L., Durafourt, B.A., Boyd, J.G. and Nasirzadeh, A.R., 2024. Non-–NonECG-gated cardiac CT angiography in acute stroke is feasible and detects sources of embolism. *International Journal of Stroke*, *19*(2), pp.189-198.
45. Zhang, M., Xiao, Q., Wang, K., Yin, R., Liu, G., Zhao, H., Li, P., Zhu, X. and Pan, X., 2024. Embolic stroke of undetermined source: Focusing on atrial cardiopathy and patent foramen ovale. International Journal of Cardiology, p.131810.
46. Komatsu, T., Okumura, M., Kida, H., Takahashi, J., Maku, T., Kitagawa, T., Sato, T., Takatsu, H., Sakuta, K., Sakai, K. and Umehara, T., 2024. Thin aortic arch plaque is associated with the development of atrial fibrillation for embolic stroke of an undetermined source in patients with an insertable cardiac monitor. International Journal of Cardiology, p.131769.
47. Montanaro, V.V.A., Silva, G.S., Oliveira Filho, J., Pontes-Neto, O.M., do Carmo Pereira Nunes, M., Bezerra, R.D.P., Sousa de Melo, E., Valenca Patrizia Alves de Andrade, L., Alves de Oliveira Junior, W., Castro Alves de Meira, F. and Teixeira, A.L., 2024. Exploring the Chagas disease-Stroke 'Connection': Findings from a Large Multicenter Study. Cerebrovascular Diseases, pp.1-1.
48. Alnaqeb, D., Si Larbi, M.T., Saba, I., Zaidan, R., Aboughanima, N.M., Alshaikh, H.M., Alzaraa, K.M., Dagumampan, L.M. and Alwhaibi, B.A., 2024. Age and Gender Difference among Elderly Stroke Patients in a Rehabilitation Center, Retrospective Study. *Physical & Occupational Therapy In Geriatrics*, pp.1-11.
49. Lee, T.T.L., Chan, S.C.L., Chou, O.H.I., Lee, S., Chan, J.S.K., Liu, T., Chang, C., Wong, W.T., Lip, G.Y., Cheung, B.M.Y. and Wai, A.K.C., 2024. Initiation of warfarin is associated with decreased mortality in patients with infective endocarditis: A population-based cohort study. *Thrombosis Research*, *233*, pp.1-9.
50. Saba, L., Cau, R., Spinato, G., Suri, J.S., Melis, M., De Rubeis, G., Antignani, P. and Gupta, A., 2024. Carotid Stenosis and Cryptogenic Stroke: The Evidence from the Imaging-based Studies Carotid Stenosis and Cryptogenic Stroke. Journal of Vascular Surgery.
51. Alhuarrat, M.A.D., Garg, V., Borkowski, P., Nazarenko, N., Alhuarrat, M.R., Abushairah, A., Al Zyoud, B., Bitsis, E.M., Barzallo, D., Alemu, R. and Kharawala, A., 2024. Epidemiologic and Clinical Characteristics of Marantic Endocarditis: A Systematic Review and Meta-Analysis of 416 Reports. *Current Problems in Cardiology*, *49*(1), p.102027.
52. Buhari, H., Fang, J., Han, L., Austin, P.C., Dorian, P., Jackevicius, C.A., Yu, A.Y., Kapral, M.K., Singh, S.M., Tu, K. and Ko, D.T., 2024. Stroke risk in women with atrial fibrillation. European Heart Journal, 45(2), pp.104-113.
53. Xu, J., Zhang, X., E, Y., Wang, W., Zhou, J., Shi, Y. and Chen, S., 2024. Relationship Between Liver Fibrosis and Increased Risk of Symptomatic Intracranial Hemorrhage in Ischemic Stroke Patients Undergoing Mechanical Thrombectomy. Neuropsychiatric Disease and Treatment, pp.101-108.
54. Mehta, V.C., Chandrasekhar, S.A., Quimby, D.L., Bhandari, A., Mazo, V., Glaser, A.D., Rose, D.Z. and Mohanty, B.D., 2024. Cerebral Protection in Trans-Catheter Aortic Valve Replacement: Review and Contemporary Assessment of Randomized Trial Data. The Neurohospitalist, p.19418744231225680.
55. Reifler, K.A., Wheelock, A., Hall, S.M., Salazar, A., Hassan, S., Bostrom, J.A., Barnett, E.D., Carrion, M., Hochberg, N.S., Hamer, D.H. and Gopal, D.M., 2024. Chagas cardiomyopathy in Boston, Massachusetts: Identifying disease and improving management after community and hospital-based screening. *PLOS Neglected Tropical Diseases*, *18*(1), p.e0011913.
56. Han, F., 2024. N6-methyladenosine modification in ischemic stroke: Functions, regulation, and therapeutic potential. *Heliyon*.
57. Zhao, G., Zhou, M., Zhao, X., Ma, C., Han, Y., Liu, J., Zhao, D., Nie, S. and CCC-ACS Investigators, 2024. Characteristics, Treatment, and In-Hospital Outcomes of Older Patients With STEMI Without Standard Modifiable Risk Factors. *JACC: Asia*, *4*(1), pp.73-83.
58. Geisler, T., Keller, T., Martus, P., Poli, K., Serna-Higuita, L.M., Schreieck, J., Gawaz, M., Tünnerhoff, J., Bombach, P., Nägele, T. and Klose, U., 2023. Apixaban versus Aspirin for Embolic Stroke of Undetermined Source. *NEJM Evidence*, *3*(1), p.EVIDoa2300235.
59. Dagra, A., Lucke-Wold, B., McGrath, K., Mehkri, I., Mehkri, Y., Davidson, C.G., Gilberstadt, N., Douglas, B.W. and Hoh, B., 2024. Central Retinal Artery Occlusion: A Review of Pathophysiological Features and Management. *Stroke: Vascular and Interventional Neurology*, *4*(1), p.e000977.
60. Chen, P.Y., Chang, W.L., Hsiao, C.L. and Lin, S.K., 2024. Seasonal Variations in Stroke and a Comparison of the Predictors of Unfavorable Outcomes among Patients with Acute Ischemic Stroke and Cardioembolic Stroke. *Biomedicines*, *12*(1), p.223.
61. Shehadeh, M., Rahhal, A., Shunnar, K., Ahmed, A.O., AlKhalaila, O., Abdelghani, M., Mahfouz, A., Alyafei, S. and Arabi, A., 2024. Percutaneous coronary intervention can be safely performed with left

ventricular thrombus without increasing stroke risk: A 5-year retrospective review using real-world data. *International Journal of Cardiology*, *395*, p.131415.
62. Hu, M., Yang, T. and Yang, Y., 2024. Causal associations of education level with cardiovascular diseases, cardiovascular biomarkers, and socioeconomic factors. *The American Journal of Cardiology*, *213*, pp.76-85.
63. Maulana, C.A., Soesanto, S.A., Nurmansyah, M.I., Mulawarman, R., Trifitriana, M., Yunanda, R. and Zulkarnain, E., 2024. Acute Ischemic Stroke with Acute Myocardial Infarction, Neurologist or Cardiologist First? A Rarely Reported Case. *International Journal of Medical Science and Clinical Research Studies*, *4*(01), pp.107-110.
64. Sharma, M., Molina, C.A., Toyoda, K., Bereczki, D., Bangdiwala, S.I., Kasner, S.E., Lutsep, H.L., Tsivgoulis, G., Ntaios, G., Czlonkowska, A. and Shuaib, A., 2024. Safety and efficacy of factor XIa inhibition with milvexian for secondary stroke prevention (AXIOMATIC-SSP): a phase 2, international, randomized, double-blind, placebo-controlled, dose-finding trial. *The Lancet Neurology*, *23*(1), pp.46-59.
65. Lindor, R.A., Heller, K., Hodgson, N.R., Kishi, P., Monas, J., Rappaport, D., Thomas, A., Urumov, A., Walker, L.E. and Majdalany, D.S., 2024. Adult Congenital Heart Disease in the Emergency Department. *Journal of Personalized Medicine*, *14*(1), p.66.
66. Uhe, T., Wasser, K., Weber-Krüger, M., Schäbitz, W.R., Köhrmann, M., Brachmann, J., Laufs, U., Dichgans, M., Gelbrich, G., Petroff, D. and Prettin, C., 2023. Intensive heart rhythm monitoring to decrease ischemic stroke and systemic embolism—the Find-AF 2 study—rationale and design. *American Heart Journal*, *265*, pp.66-76.
67. Chen, W., Wang, M., Yang, L., Wang, X., Jin, Q., Zhao, Z. and Hu, W., 2024. White matter hyperintensity burden and collateral circulation in acute ischemic stroke with large artery occlusion. *BMC neurology*, *24*(1), p.6.
68. Boot, E., Ekker, M.S., Putaala, J., Kittner, S., De Leeuw, F.E. and Tuladhar, A.M., 2020. Ischaemic stroke in young adults: a global perspective. *Journal of Neurology, Neurosurgery & Psychiatry*.
69. Kamel, H., Longstreth Jr, W.T., Tirschwell, D.L., Kronmal, R.A., Broderick, J.P., Palesch, Y.Y., Meinzer, C., Dillon, C., Ewing, I., Spilker, J.A. and Di Tullio, M.R., 2019. The AtRial Cardiopathy and Antithrombotic Drugs in Prevention After Cryptogenic Stroke Randomized Trial: Rationale and Methods. *International Journal of Stroke*, *14*(2), pp.207-214.

70. Zou, R., Wang, S., Liu, P., Chen, D., Yan, J., Cai, H., Wang, Y. and Wang, C., 2024. The association between patent foramen ovale and unexplained syncope in pediatric patients. *Italian Journal of Pediatrics*, *50*(1), p.2.
71. Rossi, P.J., Desai, N.D., Malaisrie, S.C., Lyden, S.P., Nassiri, N., Reece, T.B., Adams, J.D., Moanie, S.L., Shults, C.C., Vallabhajosyula, P. and Panneton, J., 2024. One-Year Results of a Low-Profile Endograft in Acute, Complicated Type B Aortic Dissection. *The Annals of Thoracic Surgery*, *117*(2), pp.336-343.
72. Schuett, K., Forst, T., Birkenfeld, A.L., Zirlik, A., Müller-Wieland, D. and Marx, N., 2024. Diabetes mellitus and the heart. *Experimental and Clinical Endocrinology & Diabetes*.
73. Qiao, M.L., Ma, L., Wang, C.B., Fang, L.B., Fan, Z.X., Niu, T.T., Wang, Z.Y., Lu, J.F., Yuan, B.Y. and Liu, G.Z., 2023. Clinical features, risk factors and survival in cardiac myxoma-related ischemic stroke: A multicenter case-control study. *Journal of the Neurological Sciences*, *444*, p.120517.
74. Caldonazo, T., Musleh, R., Moschovas, A., Kirov, H., Franz, M., Haeusler, K.G., Faerber, G., Doenst, T., Günther, A. and Diab, M., 2024. Antithrombotic Therapy in Patients With Infective Endocarditis: A Systematic Review and Meta-Analysis. JACC: Advances, 3(2), p.100768.
75. Khatri, P. and Kasner, S.E., 2006. Ischemic strokes after cardiac catheterization: opportune thrombolysis candidates? *Archives of Neurology*, *63*(6), pp.817-821.
76. Somani, S.S., Narayan, S.M. and Rogers, A.J., 2024. Artificial intelligence in cardiac electrophysiology. In Artificial Intelligence in Clinical Practice (pp. 475-496). Academic Press.
77. Jordan, K., Yaghi, S., Poppas, A., Chang, A.D., Mac Gregory, B., Cutting, S., Burton, T., Jayaraman, M., Tsivgoulis, G., Sabeh, M.K. and Merkler, A.E., 2019. Left atrial volume index is associated with cardioembolic stroke and atrial fibrillation detection after embolic stroke of an undetermined source. *Stroke*, *50*(8), pp.1997-2001.
78. Vecchini, F., Haupert, G., Baudry, A., Mancini, J., Dumur, L., Martinez, R., Piquet, P., Picquet, J. and Gaudry, M., 2024. Risk Factors for Incomplete Aortic Remodeling With Stent-Assisted Balloon-Induced Intimal Disruption and Relamination in Aortic Dissection Repair for Complicated Aortic Dissection: Results of a Multicenter Study. Journal of Endovascular Therapy, 31(1), pp.69-79.

79. Ioannou, P., Ziogou, A., Giannakodimos, I., Giannakodimos, A., Baliou, S. and Samonis, G., 2024. Infective Endocarditis by Lactobacillus Species—A Narrative Review. *Antibiotics*, *13*(1), p.53.
80. Gordon, H., Burisch, J., Ellul, P., Karmiris, K., Katsanos, K., Allocca, M., Bamias, G., Barreiro-de Acosta, M., Braithwaite, T., Greuter, T. and Hardwood, C., 2024. ECCO guidelines on extaintrestinal manifestations in inflammatory bowel disease. *Journal of Crohn's and Colitis*, *18*(1), pp.1-37.
81. Brenner, D.A., Valdivia, D.J., Ginalis, E.E., Dadario, N.B., Mashiach, E., Gupta, G., Sundararajan, S., Nourollah-Zadeh, E., Lazar, E., Roychowdhury, S. and Sun, H., 2024. Brain abscesses following carotid blowout syndrome: a case report. *Radiology Case Reports*, *19*(4), pp.1319-1324.
82. Nguyen, T.N., Abdalkader, M., Qureshi, M.M., Michel, P., Strambo, D., Strbian, D., Herweh, C., Möhlenbruch, M.A., Räty, S., Olive-Gadea, M. and Ribo, M., 2024. First-Line Stent Retriever Versus Contact Aspiration or Combined Technique for Endovascular Therapy of Posterior Cerebral Artery Occlusion Stroke: The PLATO Study. Stroke: Vascular and Interventional Neurology, 4(1), p.e001004.
83. Mizuki, S., Matsuo, R., Irie, F., Shono, Y., Kuwashiro, T., Sugimori, H., Wakisaka, Y., Ago, T., Kamouchi, M., Kitazono, T. and Fukuoka Stroke Registry Investigators, 2024. Body temperature in the acute phase and clinical outcomes after acute ischemic stroke. Plos one, 19(1), p.e0296639.
84. Pollari, F., Hitzl, W., Vogt, F., Cuomo, M., Schwab, J., Söhn, C., Kalisnik, J.M., Langhammer, C., Bertsch, T., Fischlein, T. and Pfeiffer, S., 2020. Aortic valve calcification is a risk factor for major complications and reduced survival after transcatheter replacement. Journal of cardiovascular computed tomography, 14(4), pp.307-313.
85. Aldweib, N. and Broberg, C., 2024. Failing with Cyanosis-Heart Failure in End-Stage Unrepaired or Partially Palliated Congenital Heart Disease. *Heart Failure Clinics*.
86. Sakai, K., Suda, S., Iguchi, Y., Abe, A., Yagita, Y., Kanzawa, T., Okubo, S., Fujimoto, S. and Kimura, K., 2024. High pre-stroke CHADS2 score predicts unfavorable functional outcome in acute cardioembolic stroke patients prescribed oral anticoagulant therapy: A sub-analysis of the PASTA registry study. *Journal of Stroke and Cerebrovascular Diseases*, *33*(2), p.107519.
87. Goldhaber, S.Z., 2024. Obesity and pulmonary embolism: can we dismantle the "obesity paradox"? *Thrombosis and Homoeostasis*, *124*(01), pp.058-060.
88. Fishel Bartal, M., Clifford, C.C., Bentum, N.A.A., Ogunye, A.A., Chen, H.Y., Chauhan, S.P. and Sibai, B.M., 2023. Risk factors and outcomes in people with stroke associated with pregnancy: A retrospective single-center cohort. *International Journal of Gynecology & Obstetrics*, *161*(3), pp.861-869.
89. Hering, D., Piper, C., Bergemann, R., Hillenbach, C., Dahm, M., Huth, C. and Horstkotte, D., 2005. Thromboembolic and bleeding complications following St. Jude Medical valve replacement: results of the German Experience With Low-Intensity Anticoagulation study. *Chest*, *127*(1), pp.53-59.
90. Shlyakhto, E.V. and Baranova, E.I., 2020. Central directions for reducing cardiovascular mortality: what can be changed today. *Rossiyskiy kardiologicheskiy zhurnal= Russian Journal of cardiology*, *7*, pp.10-18.

91. George, M.G., 2020. Risk factors for ischemic stroke in younger adults: a focused update. Stroke, 51(3), pp.729-735.
92. Ntaios, G., Perlepe, K., Lambrou, D., Sirimarco, G., Strambo, D., Eskandari, A., Karagkiozi, E., Vemmou, A., Koroboki, E., Manios, E. and Makaritsis, K., 2019. Prevalence and overlap of potential embolic sources in patients with embolic stroke of undetermined source. Journal of the American Heart Association, 8(15), p.e012858.
93. Ntaios, G., 2020. Embolic stroke of undetermined source: JACC review topic of the week. *Journal of the American College of Cardiology*, *75*(3), pp.333-340.
94. Jalini, S., Rajalingam, R., Nisenbaum, R., Javier, A.D., Woo, A. and Pikula, A., 2019. Atrial cardiopathy in patients with embolic strokes of unknown source and other stroke etiologies. *Neurology*, *92*(4), pp.e288-e294.
95. Dong, J. and Ma, X., 2022. Uncommon Female-Predominant Etiologies of Cryptogenic Stroke. *Frontiers in Neurology*, *13*, p.900991.
96. Wu, V.C.C., Wu, M., Aboyans, V., Chang, S.H., Chen, S.W., Chen, M.C., Wang, C.L., Hsieh, I.C., Chu, P.H. and Lin, Y.S., 2019. Female sex as a risk factor for ischaemic stroke varies with age in patients with atrial fibrillation. *Heart*.
97. Elsaid, N., Bigliardi, G., Dell'Acqua, M.L., Vandelli, L., Ciolli, L., Picchetto, L., Borzì, G., Ricceri, R., Pentore, R., Vallone, S. and Meletti, S., 2020. The relation between aortic arch branching types and the laterality of cardio-embolic stroke. *Journal of Stroke and Cerebrovascular Diseases*, *29*(7), p.104917.

98. Nudy, M., Chinchilli, V.M. and Foy, A.J., 2019. A systematic review and meta-regression analysis to examine the 'timing hypothesis' of hormone replacement therapy on mortality, coronary heart disease, and stroke. *IJC Heart & Vasculature*, *22*, pp.123-131.
99. Carcel, C., Woodward, M., Wang, X., Bushnell, C. and Sandset, E.C., 2020. Sex matters in stroke: a review of recent evidence on the differences between women and men. *Frontiers in Neuroendocrinology*, *59*, p.100870.
100. Kondo, T., Nakano, Y., Adachi, S. and Murohara, T., 2019. Effects of tobacco smoking on cardiovascular disease. *Circulation Journal*, *83*(10), pp.1980-1985.
101. Sulzgruber, P., Wassmann, S., Semb, A.G., Doehner, W., Widimsky, P., Gremmel, T., Kaski, J.C., Savarese, G., Rosano, G.M., Borghi, C. and Kjeldsen, K., 2019. Oral anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1: a current opinion of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Council on Stroke. *European Heart Journal-Cardiovascular Pharmacotherapy*, *5*(3), pp.171-180.